Inhaled drugs just got a lot easier to understand, thanks to new models from Simulations Plus and the University of Florida’s College of Pharmacy.

Trending News ☀️

Simulations Plus ($NASDAQ:SLP), Inc. is a leading provider of drug discovery and development software solutions. The company’s software is used by major pharmaceutical, biotechnology, agrochemical, and cosmetics companies worldwide. The U.S. Food and Drug Administration has awarded a new funded contract to Simulations Plus and the University of Florida’s College of Pharmacy to advance in vitro and physiology-based pharmacokinetics models to understand and predict pulmonary absorption and tissue retention of inhaled drugs.

Share Price

On Wednesday, SIMULATIONS PLUS stock opened at $40.5 and closed at $41.0, up by 1.4% from previous closing price of 40.5. This is important because it can help researchers develop more effective drugs and improve patient care. Live Quote….

VI Analysis

The company’s products are used for drug discovery, development, and regulatory submissions. Simulations Plus has a strong financial position, with a strong balance sheet and good cash flow. However, the company has two risk warnings in its income statement and balance sheet. Register on vi.app to check it out.

VI Peers

The company was founded in 1986 and is headquartered in Lancaster, California. Simulations Plus Inc has three main competitors: Schrodinger Inc, Intercare DX Inc, and KDA Group Inc.

– Schrodinger Inc ($NASDAQ:SDGR)

Schrodinger Inc is a publicly traded company with a market capitalization of 1.52 billion as of 2022. The company has a return on equity of -15.16%. Schrodinger is a technology and software company that focuses on improving scientific discoveries through advanced computing. The company was founded in 1990 and is headquartered in New York City.

– Intercare DX Inc ($OTCPK:ICCO)

KDA Group Inc is a provider of engineering, construction and project management services. The company has a market cap of 14.81M as of 2022 and a Return on Equity of -120.56%. KDA Group Inc provides services to a range of industries including healthcare, education, commercial and institutional. The company has a strong focus on quality and safety and is committed to providing a high level of customer service.

Summary

If you’re looking for a stock that could potentially offer strong returns, Simulations Plus is worth considering. The company provides software solutions for the pharmaceutical and biotechnology industries, and its products are used by some of the world’s largest drugmakers. The company’s strong financial performance has been driven by solid growth in its core businesses. Simulations Plus is a well-established player in the drug development market, with a long history of providing software solutions to the pharmaceutical industry.

The company’s products are used by many of the world’s largest drugmakers, and its customer base is growing. The company has no debt and is well-positioned to continue growing. Simulations Plus is an intriguing stock for investors who are looking for a company with strong growth potential.